Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.76 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.76 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.44 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.44 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | GRM8 | O00222 | 1/20 | 0.44 |
| ▸ | GRM6 | O15303 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL28776970 | 1.00 | PTGS1 (0.76) | PTGS1SLC7A11GRIK1GRIK2GRM1 | |
| Aspartic Acid SCHEMBL28090265 | 1.00 | PTGS1 (0.76) | PTGS1SLC7A11GRIK1GRIK2GRM1 | |
| Aspartic Acid SCHEMBL409120 | 1.00 | PTGS1 (0.76) | PTGS1SLC7A11GRIK1GRIK2GRM1 | |
| Aspartic Acid SCHEMBL8628354 | 0.94 | PTGS1 (0.67) | PTGS1SLC7A11GRIK1GRIK2GRM1 | |
| Aspartic Acid SCHEMBL27647865 | 0.92 | PTGS1 (0.64) | PTGS1SLC7A11GRIK1GRIK2GRM1 | |
| Aspartic Acid SCHEMBL3247000 | 0.92 | PTGS1 (0.64) | PTGS1SLC7A11GRIK1GRIK2GRM1 | |
| Glutamic Acid SCHEMBL2999431 | 0.88 | GRM8 (0.67) | PTGS1SLC7A11GRIK1GRIK2GRM1 | |
| Aspartic Acid SCHEMBL7706079 | 0.87 | PTGS1 (0.55) | PTGS1SLC7A11GRIK1GRIK2GRM1 | |
| Cysteine SCHEMBL1868335 | 0.87 | PTGS1 (1.00) | PTGS1SLC7A11GRIK1GRIK2GRM1 | |
| Cysteine SCHEMBL5705430 | 0.87 | PTGS1 (1.00) | PTGS1SLC7A11GRIK1GRIK2GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112011499-B | Method for preparing extracellular vesicles and application thereof | 徐州医科大学 | 2022-06-03 | — | — | CN | claimed |
| CN-113181175-A | Application of epalrestat as inhibitor for specifically targeting NLRP3 inflammatory bodies | 中国人民解放军总医院第五医学中心 | 2021-07-30 | — | — | CN | claimed |
| CN-109536546-B | Preparation method and application of medium-small molecular weight oat beta-glucan | 上海晟薇生物科技有限公司 | 2021-03-19 | — | — | CN | claimed |
| CN-112294828-A | Use of cryptotanshinone as inflammation inhibitor | 中国人民解放军总医院第五医学中心 | 2021-02-02 | — | — | CN | claimed |
| CN-112011499-A | Method for preparing extracellular vesicles and application thereof | 徐州医科大学 | 2020-12-01 | — | — | CN | claimed |
| CN-110638861-A | Application of composition in skin barrier gene repair | 上海珈凯生物科技有限公司 | 2020-01-03 | — | — | CN | claimed |
| CN-105765067-A | Modified beta-galactosidase | 天野酶株式会社 | 2016-07-13 | — | — | CN | claimed |
| US-4632703-A | SULFONATED PHTHALOCYANINE DYE; ESPECIALLY FOR INK JET PRINTING | CANON KABUSHIKI KAISHA (JP) | 1986-12-30 | — | — | US | claimed |
| EP-4722232-A1 | SINGLE-CHAIN POLYPEPTIDE ACTIVATED IN USE | YSTE (Hainan) Aesthetic Medicine Health Technology Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12576076-B2 | Use of HSP70 as a regulator of enzymatic activity | Zevra Denmark A/S (DK) | 2026-03-17 | — | — | US | disclosed |
| US-12570743-B2 | BCMA-targeting engineered immune cell and use thereof | GRACELL BIOSCIENCE (SHANGHAI) CO., LTD. (CN) | 2026-03-10 | — | — | US | disclosed |
| US-20250262269-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-08-21 | — | — | US | disclosed |
| CN-119302983-B | CIRCWRNIP1 and application of related reagent in regulation and control of chicken follicular development | 成都市农林科学院 | 2025-06-17 | — | — | CN | disclosed |
| CN-120114479-A | Cerium oxide nano enzyme delivery system based on carrying neutrophils | 吉林大学 | 2025-06-10 | — | — | CN | disclosed |
| WO-1999045944-A1 | PROAPOPTOTIC PEPTIDES, DEPENDENCE POLYPEPTIDES AND METHODS OF USE | THE BURNHAM INSTITUTE (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999018230-A2 | METHOD TO DETECT MRIT AND BCL-2 OR CASPASE ASSOCIATION ALTERATIONS | UNIVERSITY OF WASHINGTON (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1998024472-A9 | USES OF THIOREDOXIN | — | 1999-02-04 | — | — | WO | disclosed |
| WO-1998055863-A1 | RAPID METHODS FOR IDENTIFYING MODIFIERS OF CELLULAR APOPTOSIS ACTIVITY | IDUN PHARMACEUTICALS, INC. (US) | 1998-12-10 | — | — | WO | disclosed |
| EP-0575304-B1 | Sulfonamide peroxycarboxylic acids | AKZO NOBEL NV (NL) | 1996-09-25 | — | — | EP | disclosed |
| EP-0575304-A1 | Sulfonamide peroxycarboxylic acids | Akzo Nobel N.V. (NL) | 1993-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576076-B2 | Use of HSP70 as a regulator of enzymatic activity | HSPB1, HSPA1B, HSPD1 | PTGS1 289/4885SLC7A11 3550/4885GRIK1 4741/4885 |
| US-12570743-B2 | BCMA-targeting engineered immune cell and use thereof | TNFRSF9, CD74, CD40 | PTGS1 4290/4885SLC7A11 3291/4885GRIK1 3870/4885 |
| US-20250262269-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | RNPEP, TNNI3, BDKRB1 | PTGS1 3431/4885SLC7A11 211/4885GRIK1 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.